ExpreS2ion Biotech Holding (EXPRS2) Stock Overview
A clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
EXPRS2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
ExpreS2ion Biotech Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.25 |
| 52 Week High | SEK 22.85 |
| 52 Week Low | SEK 1.10 |
| Beta | 2.17 |
| 1 Month Change | -12.89% |
| 3 Month Change | -21.38% |
| 1 Year Change | -93.06% |
| 3 Year Change | -98.04% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| EXPRS2 | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.4% | -2.8% | -1.4% |
| 1Y | -93.1% | 20.3% | 11.9% |
Return vs Industry: EXPRS2 underperformed the Swedish Biotechs industry which returned 20.3% over the past year.
Return vs Market: EXPRS2 underperformed the Swedish Market which returned 11.9% over the past year.
Price Volatility
| EXPRS2 volatility | |
|---|---|
| EXPRS2 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in SE Market | 10.6% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: EXPRS2's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: EXPRS2's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 19 | Bent Frandsen | expres2ionbio.com |
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company’s lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins.
ExpreS2ion Biotech Holding AB (publ) Fundamentals Summary
| EXPRS2 fundamental statistics | |
|---|---|
| Market cap | SEK 29.69m |
| Earnings (TTM) | -SEK 35.91m |
| Revenue (TTM) | SEK 24.25m |
Is EXPRS2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXPRS2 income statement (TTM) | |
|---|---|
| Revenue | SEK 24.25m |
| Cost of Revenue | SEK 3.50m |
| Gross Profit | SEK 20.75m |
| Other Expenses | SEK 56.66m |
| Earnings | -SEK 35.91m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 12, 2026
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 85.57% |
| Net Profit Margin | -148.11% |
| Debt/Equity Ratio | 1.4% |
How did EXPRS2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 10:22 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ExpreS2ion Biotech Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |